MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.560 +0.010 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and... 
Via Talk Markets
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Artificial Intelligence
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
--News Direct-- 
Via News Direct
Topics Artificial Intelligence
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
By Faith Ashmore, Benzinga 
Via TheNewswire.com
News headline image
The Latest Analyst Ratings for Compass Pathways ↗
 
Via Benzinga
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
--News Direct-- 
Via News Direct
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
News headline image
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
News headline image
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing ↗
Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by... 
Via Benzinga
News headline image
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... 
Via Talk Markets
News headline image
Swedish Foundation Supports Mental Health Innovation With New €3M Psychedelic Science Initiative ↗
The Norrsken Foundation, a non-profit impact ecosystem “connecting founders with the capital, knowledge and network they need to make saving the world their business,” is launching a $3.22 (&e 
Via Benzinga
What’s Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field
--News Direct-- 
Via News Direct
Topics Intellectual Property
News headline image
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
News headline image
What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field ↗
In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS), consisting of an initial investment of... 
Via Benzinga
News headline image
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
Via Talk Markets
News headline image
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression ↗
COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COM 
Via Benzinga
Topics Artificial Intelligence
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
News headline image
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15% ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
News headline image
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
News headline image
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street ↗
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders. 
Via The Motley Fool
News headline image
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week ↗
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
News headline image
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
News headline image
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
News headline image
COMPASS' Securities Purchase Agreement Is Big News ↗
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. ... 
Via Benzinga
Topics Cannabis
News headline image
Up To $285M In Financing: COMPASS Pathways' Private Placement Backed By 'Select Group' Of Investors ↗
Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of... 
Via Benzinga
News headline image
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
News headline image
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
News headline image
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA ↗
Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story